NEW YORK, NY - Synbio International, Inc. (OTC: SYIN) has announced the commencement of revenue-generating operations with the launch of its Healing Force™ nutraceutical division and first consumer product, Healing Force™ Anxiety Relief. This strategic move transitions the company from a development-stage entity to an operating business, combining near-term commercial opportunities with long-term growth potential in AI-driven healthcare.
The first product under the Healing Force™ brand is a natural wellness formulation designed to support individuals seeking non-pharmaceutical approaches to managing everyday stress and anxiety. Unlike pharmaceutical products, nutraceuticals can be marketed without lengthy pre-market approval processes, enabling rapid commercialization. Claudio Solitario, CEO of Synbio International, emphasized that this launch is more than a single product; it marks the beginning of a strategy to create sustainable shareholder value through multiple revenue streams.
The global nutraceuticals market is poised for significant growth, projected to expand from approximately US$684 billion today to over US$1.1 trillion by 2033. This surge is driven by increasing consumer demand for preventative healthcare and natural wellness products. Synbio aims to capitalize on this trend by entering the sector at an opportune time, with additional wellness formulations under evaluation for future commercialization.
The Healing Force™ product line is developed under the guidance of Dr. David Anderson, M.D., who brings decades of experience in nutraceutical research and product development. His background includes roles as a Research Physician and Senior Research Scientist, coordinating programs with academic institutions, physicians, and government agencies. Dr. Anderson stressed the importance of evidence-based wellness solutions, aligning with consumer preferences for natural approaches to stress management and emotional well-being.
Synbio's commercialization strategy prioritizes capital efficiency, initially marketing and distributing Healing Force™ products through direct-to-consumer online channels. This approach, supported by targeted digital marketing and e-commerce initiatives, is designed to enable rapid scaling while preserving financial flexibility as the product portfolio expands.
Beyond nutraceuticals, Synbio continues to advance its healthcare technology initiatives, including the validation of the FacialDx Inc. facial analysis platform for mental health. The company's dual-track strategy balances near-term revenue generation with longer-term technology development, positioning it to create multiple sources of revenue and sustainable growth.
The launch of Healing Force™ represents a pivotal milestone for Synbio, transitioning from years of restructuring and partnerships to active commercial operations. As the company begins executing its revenue generation strategy, it aims to establish a diversified wellness and healthcare platform that addresses both immediate market needs and future technological advancements.
